Evidence matrix
These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.
What has been shown in humans?
Human evidence is fragmented across exercise, cardiovascular, metabolic and condition-specific studies. It is not yet a coherent longevity evidence base. A registered older-adult trial should help by testing functional and biological ageing outcomes rather than lifespan itself.
What remains uncertain?
The effective dose, target population, duration, long-term safety in older adults and relevance of animal lifespan findings to humans are unresolved. Blood taurine concentration is also influenced by diet, kidney handling and other physiology, so a low level is not automatically a deficiency diagnosis.
Doses used in research
Safety and interpretation
- Short studies usually report good tolerability, but long-term high-dose data in broadly healthy older adults are limited.
- People with kidney, liver or cardiovascular disease, pregnancy, or regular medicines should discuss supplementation with a clinician or pharmacist.
- Energy-drink evidence cannot be treated as taurine-only evidence because caffeine and other ingredients confound the result.
Primary sources and evidence reviews
Influential multi-species study; lifespan extension was demonstrated in animals, while human data were observational.
Registry record for an ongoing human study. Status and dates should always be checked on the live record.
Editorial note
This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.